Taxa Technologies is a technology company.
Taxa Technologies has raised $3.0M across 1 funding round.
Taxa Technologies has raised $3.0M in total across 1 funding round.
Taxa Technologies has raised $3.0M in total across 1 funding round.
Taxa Technologies's investors include 10T Holdings, Alpha Square Group, Conversion Capital, DST Global, Evolution VC Partners, Haymaker Ventures, Intel Capital, Magma Partners, Morgan Creek Capital Management, MUFG Innovation Partners, Quantum Angels Venture Capital, Ulu Ventures.
Taxa Technologies is a biotechnology company founded in 2023, specializing in synthetic biology to engineer the human microbiome for personal care applications[1][3][5]. It develops gene-editing methods to recode microbiome genes at subspecies resolution, creating tailored ingredients like a one-week deodorant with probiotics that reduce body odor, absorb UV, and repel mosquitoes[1][2][4]. Targeting consumers facing unmet needs in skin health, the company serves personal care manufacturers with microbiome-modulated solutions, emphasizing a consumer-first, technology-agnostic approach over traditional tech-push models[1][5]. Backed by a $2.5M oversubscribed pre-seed round, it shows early growth momentum with plans to build a multidisciplinary team and expand from Japan to the US and Europe[3][5].
Taxa Technologies emerged in 2023 in San Francisco (with some sources noting 2024 and Chico, CA, possibly indicating rapid evolution or data variance), founded by Xavier Segel (CEO) and Yuichi Fukunaga (COO), leveraging expertise in synthetic biology and microbiome research[1][3][5]. Segel's consumer-first vision stemmed from identifying everyday problems like body odor and skin functionality, applying 'omics data and gene-editing tools to microbiome engineering—a complex, unsolved biotech challenge[1][5]. Early traction includes an oversubscribed $2.5M pre-seed led by Boost VC, with participation from Midnight Venture Partners, Space Cadet Ventures, and Savantus Ventures, fueling team expansion[3][5]. Pivotal moments highlight its nimble pivot readiness and focus on subspecies-level precision, distinguishing it from typical synbio firms[1].
Taxa rides the synthetic biology wave intersecting with the $500B+ personal care market, where microbiome modulation addresses rising demand for natural, long-lasting, non-toxic products amid clean beauty trends[1][2][5]. Timing aligns with advances in 'omics and CRISPR-like tools enabling precise human microbiome engineering, previously unsolved, fueling a "renaissance" in hygiene via biotech[1][5]. Market forces like consumer skepticism of chemicals and Japan/US expansion favor its approach, influencing the ecosystem by proving consumer-led synbio viability—potentially disrupting giants with tailored, probiotic-driven ingredients and inspiring pharma-like top-down personalization[5].
Taxa Technologies is poised to scale its $2.5M-funded platform into commercial personal care launches, starting in Japan via Fukunaga's network, then US/Europe, building a multidisciplinary team for rapid iteration[3][5]. Trends like microbiome therapeutics, clean beauty, and synbio personalization will propel growth, with potential for $100M+ revenue trajectories mirroring team alumni successes. Its influence may evolve from niche innovator to category leader, redefining hygiene by bridging biotech precision with consumer needs—echoing its founding hook of solving real problems with nimble, impactful tech.
Taxa Technologies has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in February 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2024 | $3.0M Seed | 10T Holdings, Alpha Square Group, Conversion Capital, DST Global, Evolution VC Partners, Haymaker Ventures, Intel Capital, Magma Partners, Morgan Creek Capital Management, MUFG Innovation Partners, Quantum Angels Venture Capital, Ulu Ventures, Anthony Pompliano |